Periscope Capital’s Ibere Pharmaceuticals Units, each consisting of one Class A ordinary share and one-half of one Redeemable Warrant IBER.U Stock Holding History

Periscope Capital’s Portfolio IBER.U Stock Details IBER.U Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-250,000	Closed	-$2.5M	–	1072
2021 Q3	$2.5M	Hold	250,000	–	–	0.07%	444
2021 Q2	$2.51M	Hold	250,000	–	–	0.08%	407
2021 Q1	$2.46M	Buy	+250,000	New	+$2.5M	0.1%	344

Other funds holding IBER.U

Hartree Partners New York $467M AUM 66.71% 1-Year Est. Return

Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return

Kryger Capital London, United Kingdom $1.41B AUM 86.31% 1-Year Est. Return

Aristeia Capital Greenwich, Connecticut $4.82B AUM 24.94% 1-Year Est. Return

Calamos Advisors Naperville, Illinois $28.2B AUM 21.78% 1-Year Est. Return

Wealthspring Capital West Harrison, New York $448M AUM 8.38% 1-Year Est. Return

SIA

Schechter Investment Advisors Birmingham, Michigan $1.21B AUM 8.73% 1-Year Est. Return

CCM

Context Capital Management Lajolla, California $4.33B AUM 1.35% 1-Year Est. Return

SMA

Sage Mountain Advisors Atlanta, Georgia $1.43B AUM 16.47% 1-Year Est. Return

HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return

Periscope Capital's IBER.U Position: Q4 2021 in Review

Periscope Capital sold out of Ibere Pharmaceuticals Units, each consisting of one Class A ordinary share and one-half of one Redeemable Warrant (IBER.U) in Q4 2021, closing a stake of 250,000 shares — an estimated $2.5M sold.

Periscope Capital first reported a position in IBER.U in Q1 2021 and held it in 3 quarters. The position peaked at $2.51M in Q2 2021. 23 funds tracked by Wall St. Rank hold IBER.U as of Q4 2021.

Periscope Capital reported no remaining Ibere Pharmaceuticals Units, each consisting of one Class A ordinary share and one-half of one Redeemable Warrant position as of Q4 2021 after selling out during the quarter.
Periscope Capital sold 250,000 Ibere Pharmaceuticals Units, each consisting of one Class A ordinary share and one-half of one Redeemable Warrant shares in Q4 2021, an estimated $2.5M.
Periscope Capital first reported a position in Ibere Pharmaceuticals Units, each consisting of one Class A ordinary share and one-half of one Redeemable Warrant in Q1 2021 and held it in 3 quarters.
Periscope Capital's Ibere Pharmaceuticals Units, each consisting of one Class A ordinary share and one-half of one Redeemable Warrant position peaked at $2.51M in Q2 2021.
23 funds tracked by Wall St. Rank held Ibere Pharmaceuticals Units, each consisting of one Class A ordinary share and one-half of one Redeemable Warrant as of Q4 2021.

Based on Periscope Capital's 13F filing for Q4 2021, filed 14 Feb 2022.